Literature DB >> 489300

Simulants of lung interstitial fluid.

O R Moss.   

Abstract

Mesh：

Substances：

Year:  1979        PMID： 489300

Source DB:  PubMed          Journal:  Health Phys        ISSN： 0017-9078            Impact factor:   1.316


× No keyword cloud information.
  19 in total

1.  Solid lipid budesonide microparticles for controlled release inhalation therapy.

Authors:  Matteo Mezzena; Santo Scalia; Paul M Young; Daniela Traini
Journal:  AAPS J       Date:  2009-11-12       Impact factor: 4.009

2.  Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).

Authors:  Jahidur Rashid; Brijeshkumar Patel; Eva Nozik-Grayck; Ivan F McMurtry; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2017-02-07       Impact factor: 9.776

3.  Bioaccessibility of As, Cu, Pb, and Zn in mine waste, urban soil, and road dust in the historical mining village of Kaňk, Czech Republic.

Authors:  Petr Drahota; Karel Raus; Eva Rychlíková; Jan Rohovec
Journal:  Environ Geochem Health       Date:  2017-06-15       Impact factor: 4.609

4.  An inhalation-ingestion bioaccessibility assay (IIBA) for the assessment of exposure to metal(loid)s in PM10.

Authors:  Farzana Kastury; E Smith; Ranju R Karna; Kirk G Scheckel; A L Juhasz
Journal:  Sci Total Environ       Date:  2018-03-07       Impact factor: 7.963

5.  Impacts of Antioxidants on Hydroxyl Radical Production from Individual and Mixed Transition Metals in a Surrogate Lung Fluid.

Authors:  Jessica G Charrier; Cort Anastasio
Journal:  Atmos Environ (1994)       Date:  2011-11       Impact factor: 4.798

6.  PLGA microparticles encapsulating prostaglandin E1-hydroxypropyl-β-cyclodextrin (PGE1-HPβCD) complex for the treatment of pulmonary arterial hypertension (PAH).

Authors:  Vivek Gupta; Marauo Davis; Louisa J Hope-Weeks; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2011-04-06       Impact factor: 4.200

7.  In vitro aqueous fluid-capacity-limited dissolution testing of respirable aerosol drug particles generated from inhaler products.

Authors:  Deepika Arora; Kumar A Shah; Matthew S Halquist; Masahiro Sakagami
Journal:  Pharm Res       Date:  2010-03-13       Impact factor: 4.200

8.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

9.  Aerosolized montelukast polymeric particles-an alternative to oral montelukast-alleviate symptoms of asthma in a rodent model.

Authors:  Brijeshkumar Patel; Nilesh Gupta; Fakhrul Ahsan
Journal:  Pharm Res       Date:  2014-06-17       Impact factor: 4.200

10.  Toxicity assessment of metal oxide nanomaterials using in vitro screening and murine acute inhalation studies.

Authors:  Sudartip Areecheewakul; Andrea Adamcakova-Dodd; Brittany E Givens; Benjamin R Steines; Yifang Wang; David K Meyerholz; Nathanial J Parizek; Ralph Altmaier; Ezazul Haque; Patrick T O'Shaughnessy; Aliasger K Salem; Peter S Thorne
Journal:  NanoImpact       Date:  2020-02-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.